查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1446477

抗凝血剂市场规模、份额、趋势分析报告：按药物分类、给药途径、应用、地区和细分市场预测，2024-2030年

Anticoagulants Market Size, Share & Trends Analysis Report By Route of Administration, By Drug Category, By Application, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10个工作天内

价格

抗凝血剂市场成长与趋势：

Grand View Research, Inc.的最新报告显示，到2030年，全球抗凝血药物市场预计将达到604亿美元，在2024-2030年预测期内复合年增长率为8.7%。

这个市场主要是由心血管疾病（CVD）盛行率的增加和人口老化所推动的。根据世界卫生组织统计，2019年，CVD造成了全球大部分死亡，死亡人数达1,790万人，占全球死亡人数的32%。其中 85% 的死亡是由于心臟病和中风造成的。此外，在因非传染性疾病导致的 1,700 万人过早死亡中，38% 是由于心血管疾病。

此外，久坐的生活方式由于缺乏身体活动而导致全球血栓增加，从而增加了对抗凝剂的需求。缺乏身体活动会增加静脉血栓栓塞症(VTE) 的风险，包括肺动脉栓塞(PE) 和深层静脉栓塞症血栓 (DVT)。当腿部深层静脉形成血块时，就会发生深部静脉血栓（DVT）；当血块从深部静脉流向肺部时，就会发生肺栓塞（PE）。根据美国国家医学图书馆的数据，VTE（包括 DVT 和 PE）每年影响美国约 90 万人。结果，数十万人住院，约30万人死亡。 VTE 盛行率的增加和对有效治疗方案的需求不断增加预计将推动市场发展。

此外，它还透过促进技术创新、提高抗凝血治疗的有效性和安全性以及改善患者监测和结果，在振兴抗凝血市场方面发挥关键作用。药物发现和开发的进步导致新型抗凝血剂具有改进的特性，例如更长的半衰期、减少与其他药物的相互作用以及降低出血风险。这些新型抗凝血剂为患者提供了更多的治疗选择和更好的结果。据美国国立卫生研究院称，基因疗法是一种治疗血栓的新方法，利用基因来纠正导致血栓的潜在遗传缺陷。儘管这种方法仍处于开发的早期阶段，但它有可能成为有效治疗方法血栓的方法。例如，2022年11月，FDA核准基因治疗药物Hemgenix用于治疗使用预防性因子IX製剂反覆严重出血的B型血友病型血友病成年患者。这是一种一次性基因疗法，将凝血因子 IX 的基因注射到肝臟。

抗凝血剂市场报告亮点

  • 新型口服抗凝血剂 (NOAC) 由于易于使用且减少了监测需求，有助于提高治疗方案的依从性，因此在 2023 年占据药物类别细分市场的主导地位。
  • 肝素和低分子肝素 (LMWH) 领域预计在预测期内将以最快的复合年增长率成长。
  • 口服製剂细分市场在 2023 年占据最大市场占有率，预计在预测期内成长最快。
  • 久坐的生活方式、吸烟率的增加和空气污染的增加导致心血管疾病的盛行率增加。
  • 由于心律不整监测和管理的重要性日益增加，心房颤动/心肌梗塞（心臟病发作）在 2023 年占据了应用领域的主导地位。
  • 由于先进的医疗基础设施、有利的法规环境以及公众对抗凝血治疗的认识不断提高等因素，北美占据了市场主导地位。
  • 2022年2月，FDA授予拜耳公司抗凝血剂Asundexian（BAY2433334）快速通道资格。这种口服血栓症因子是。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章抗凝血剂市场：变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 抗凝血剂市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章抗凝血药市场：药品分类预估及趋势分析

  • 2023年及2030年药品分类市场占有率
  • 细分仪表板
  • 按药物分类的全球抗凝血剂市场展望
  • 2018年至2030年市场规模、预测与趋势分析

第五章抗凝血药物市场：给药途径预估及趋势分析

  • 2023 年及 2030 年给药途径市场占有率
  • 细分仪表板
  • 按给药途径的全球抗凝血剂市场展望
  • 2018年至2030年市场规模、预测与趋势分析

第六章抗凝血剂市场：应用估算与趋势分析

  • 2023年及2030年应用市场占有率
  • 细分仪表板
  • 全球抗凝血剂市场应用展望
  • 2018年至2030年市场规模、预测与趋势分析

第七章抗凝血药物市场：区域估算及趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概述
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商形势
    • Aspen Holdings
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • GSK plc
    • Sanofi
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • DAIICHI SANKYO COMPANY, LIMITED
    • Johnson &Johnson Services, Inc.
    • Eisai Co., Ltd.
Product Code: GVR-4-68040-191-0

Anticoagulants Market Growth & Trends:

The global anticoagulants market is anticipated to reach USD 60.4 billion by 2030 and is expected to expand at a CAGR of 8.7% during the forecast period of 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of cardiovascular diseases (CVDs) and growing aging population. According to WHO, in 2019, CVDs caused majority of deaths worldwide, accounting for 17.9 million fatalities, which is 32% of global deaths. Among these deaths, 85% were attributed to heart attack and stroke. Moreover, of the 17 million premature deaths caused by noncommunicable diseases, 38% were due to CVDs in the same year.

Moreover, sedentary lifestyles significantly contribute to the global rise of blood clots owing to physical inactivity, fueling the demand for anticoagulants. Physical inactivity has been linked to an increased risk of venous thromboembolism (VTE), a condition that encompasses pulmonary embolism (PE) and deep vein thrombosis (DVT). The condition arises when a blood clot occurs in a deep vein in the legs, while PE occurs when a blood clot travels from a deep vein to the lungs. As per the National Library of Medicine, VTE, which includes DVT and PE, impacts around 900,000 individuals in the U.S. annually. This led to several hundred thousand hospitalizations and approximately 300,000 deaths. The increasing prevalence of VTE and the growing demand for effective treatment options is expected to boost the market.

Furthermore, technological advancements are playing a significant role in boosting the anticoagulants market by driving innovation, improving the efficacy and safety of anticoagulant treatments, and enhancing patient monitoring and outcomes. Advancements in drug discovery and development have led to the creation of new anticoagulants with improved properties, such as longer half-lives, fewer interactions with other medications, and reduced bleeding risks. These novel anticoagulants offer patients more treatment options and better outcomes. According to NIH, gene therapy is a new approach for treatment of blood clots that involves the use of genes to correct the underlying genetic defect that causes clotting. This approach is still in its early stage of development but has potential to be an effective treatment for blood clots. For instance, in November 2022, the FDA approved Hemgenix, a gene therapy to treat adults with hemophilia B who are using Factor IX prophylaxis and have a history of repeated, serious bleeding episodes. It is a one-time gene therapy that delivers a gene for clotting factor IX to the liver.

Anticoagulants Market Report Highlights:

  • Novel oral anticoagulants (NOACs) dominated the drug category segment in 2023 owing to their ease of use and reduced need for monitoring, contributing to better adherence to treatment plans
  • The Heparin and Low Molecular Weight Heparin (LMWH) segment is expected to grow at the fastest CAGR over the forecast period.
  • The oral segment held the largest market share in 2023 and is expected to witness fastest growth over the forecast period.
  • Sedentary lifestyle, increasing incidence of smoking, and rising air pollution are contributing to the growing prevalence of cardiovascular diseases
  • Atrial fibrillation/myocardial infarction (Heart attack) dominated the application segment in 2023 owing to rising importance of monitoring and managing arrhythmia
  • North America dominated the market owing to factors such as advanced healthcare infrastructure, favorable regulatory environment and rising public awareness of anticoagulant therapy
  • In February 2022, FDA granted Bayer AG's anticoagulant Asundexian (BAY2433334) Fast-Track designation. The oral factor Xla inhibitor is currently undergoing phase 2 trials for the potential prevention of secondary thrombosis in patients with non-cardioembolic ischemic stroke, atrial fibrillation, or more recently myocardial infarction.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug category
    • 1.2.2. Route of administration
    • 1.2.3. Application
  • 1.3. Regional scope
  • 1.4. Estimates and forecasts timeline
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased database
    • 1.6.2. GVR's internal database
    • 1.6.3. Secondary sources
    • 1.6.4. Primary research
    • 1.6.5. Details of primary research
      • 1.6.5.1. Data for primary interviews in North America
      • 1.6.5.2. Data for primary interviews in Europe
      • 1.6.5.3. Data for primary interviews in Asia Pacific
      • 1.6.5.4. Data for primary interviews in Latin America
      • 1.6.5.5. Data for Primary interviews in MEA
  • 1.7. Information or Data Analysis
    • 1.7.1. Data analysis models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity flow analysis (Model 1)
    • 1.9.2. Approach 1: Commodity flow approach
    • 1.9.3. Volume price analysis (Model 2)
    • 1.9.4. Approach 2: Volume price analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Primary Sources
  • 1.12. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Technology outlook
    • 2.2.2. Treatment outlook
    • 2.2.3. Application outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Anticoagulants Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of chronic diseases
      • 3.2.1.2. Technological advancements in development of anticoagulant products
      • 3.2.1.3. Growing adoption of Novel Oral Anticoagulants (NOACs)
      • 3.2.1.4. Rising geriatric population and increase prevalence of obesity
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High price associated with Novel Oral Anticoagulants (NOACs)
      • 3.2.2.2. Stringent government regulations and poor demand in underdeveloped countries
  • 3.3. Anticoagulants Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Anticoagulants Market: Drug Category Estimates & Trend Analysis

  • 4.1. Drug Category Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Anticoagulants Market by Drug Category Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Novel oral anticoagulants (NOACs)
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Eliquis
      • 4.4.1.3. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Xarelto
      • 4.4.1.5. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.6. Savaysa & Lixiana
      • 4.4.1.7. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.8. Pradaxa
      • 4.4.1.9. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Heparin and Low Molecular Weight Heparin (LMWH)
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Vitamin k Antagonist
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Direct thrombin inhibitors
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Others
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Anticoagulants Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Route of Administration Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Anticoagulants Market by Treatment Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Oral anticoagulants
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Injectable anticoagulants
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Anticoagulants Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Anticoagulants Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Atrial Fibrillation/Myocardial Infarction (Heart Attack)
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.2. Deep Vein Thrombosis (DVT)
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Pulmonary Embolism
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Others
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Anticoagulants Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Aspen Holdings
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Pfizer Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Bristol-Myers Squibb Company
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. GSK plc
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Sanofi
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Bayer AG
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Boehringer Ingelheim International GmbH
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. DAIICHI SANKYO COMPANY, LIMITED
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Johnson & Johnson Services, Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Eisai Co., Ltd.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America anticoagulants market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 4 North America anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 North America anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 7 U.S. anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 8 U.S. anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 9 Canada anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 10 Canada anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11 Canada anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 12 Europe anticoagulants market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 14 Europe anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 Europe anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 16 Germany anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 17 Germany anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Germany anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 19 UK anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 20 UK anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 21 UK anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 22 France anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 23 France anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24 France anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 25 Italy anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 26 Italy anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 Italy anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 28 Spain anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 29 Spain anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 30 Spain anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 31 Denmark anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 32 Denmark anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 33 Denmark anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 34 Sweden anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 35 Sweden anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 36 Sweden anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 37 Norway anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 38 Norway anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 Norway anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific anticoagulants market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 44 China anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 45 China anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 46 China anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 47 Japan anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 48 Japan anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 49 Japan anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 50 India anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 51 India anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 52 India anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 53 South Korea anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 54 South Korea anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 55 South Korea anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 56 Australia anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 57 Australia anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 58 Australia anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 59 Thailand anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 60 Thailand anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61 Thailand anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 62 Latin America anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 63 Latin America anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 64 Latin America surgical ablation market, by application, 2018 - 2030 (USD Million)
  • Table 65 Latin America laparoscopic ablation market, by application, 2018 - 2030 (USD Million)
  • Table 66 Latin America percutaneous ablation market, by application, 2018 - 2030 (USD Million)
  • Table 67 Latin America anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 68 Brazil anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 69 Brazil anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 70 Brazil surgical ablation market, by application, 2018 - 2030 (USD Million)
  • Table 71 Brazil laparoscopic ablation market, by application, 2018 - 2030 (USD Million)
  • Table 72 Brazil percutaneous ablation market, by application, 2018 - 2030 (USD Million)
  • Table 73 Brazil anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 74 Mexico anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 75 Mexico anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 Mexico surgical ablation market, by application, 2018 - 2030 (USD Million)
  • Table 77 Mexico laparoscopic ablation market, by application, 2018 - 2030 (USD Million)
  • Table 78 Mexico percutaneous ablation market, by application, 2018 - 2030 (USD Million)
  • Table 79 Mexico anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 80 Argentina anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 81 Argentina anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 82 Argentina surgical ablation market, by application, 2018 - 2030 (USD Million)
  • Table 83 Argentina laparoscopic ablation market, by application, 2018 - 2030 (USD Million)
  • Table 84 Argentina percutaneous ablation market, by application, 2018 - 2030 (USD Million)
  • Table 85 Argentina anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 86 MEA anticoagulants market, by region, 2018 - 2030 (USD Million)
  • Table 87 MEA anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 88 MEA anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 MEA anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 90 South Africa anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 91 South Africa anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 92 South Africa anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 93 Saudi Arabia anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 94 Saudi Arabia anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 95 Saudi Arabia anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 96 UAE anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 97 UAE anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 98 UAE anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 99 Kuwait anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 100 Kuwait anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 101 Kuwait anticoagulants market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Anticoagulants market: market outlook
  • Fig. 14 Anticoagulants competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Anticoagulants market driver impact
  • Fig. 20 Anticoagulants market restraint impact
  • Fig. 21 Anticoagulants market strategic initiatives analysis
  • Fig. 22 Anticoagulants market: Drug category movement analysis
  • Fig. 23 Anticoagulants market: Drug category outlook and key takeaways
  • Fig. 24 Novel oral anticoagulants (NOACs) market estimates and forecast, 2018 - 2030
  • Fig. 25 Heparin and Low Molecular Weight Heparin (LMWH) estimates and forecast, 2018 - 2030
  • Fig. 26 Vitamin k Antagonist market estimates and forecast, 2018 - 2030
  • Fig. 27 Direct thrombin inhibitors estimates and forecast, 2018 - 2030
  • Fig. 28 Others estimates and forecast, 2018 - 2030
  • Fig. 29 Anticoagulants Market: Route of administration movement Analysis
  • Fig. 30 Anticoagulants market: Route of administration outlook and key takeaways
  • Fig. 31 Oral anticoagulants market estimates and forecasts, 2018 - 2030
  • Fig. 32 Injectable anticoagulants market estimates and forecasts,2018 - 2030
  • Fig. 33 Anticoagulants market: Application movement analysis
  • Fig. 34 Anticoagulants market: Application outlook and key takeaways
  • Fig. 35 Atrial fibrillation/myocardial infarction (heart attack) market estimates and forecasts, 2018 - 2030
  • Fig. 36 Deep Vein Thrombosis (DVT) market estimates and forecasts,2018 - 2030
  • Fig. 37 Pulmonary embolism market estimates and forecasts, 2018 - 2030
  • Fig. 38 Other market estimates and forecasts,2018 - 2030
  • Fig. 39 Global anticoagulants market: Regional movement analysis
  • Fig. 40 Global anticoagulants market: Regional outlook and key takeaways
  • Fig. 41 Global anticoagulants market share and leading players
  • Fig. 42 North America market share and leading players
  • Fig. 43 Europe market share and leading players
  • Fig. 44 Asia Pacific market share and leading players
  • Fig. 45 Latin America market share and leading players
  • Fig. 46 Middle East & Africa market share and leading players
  • Fig. 47 North America: SWOT
  • Fig. 48 Europe SWOT
  • Fig. 49 Asia Pacific SWOT
  • Fig. 50 Latin America SWOT
  • Fig. 51 MEA SWOT
  • Fig. 52 North America, by country
  • Fig. 53 North America
  • Fig. 54 North America market estimates and forecasts, 2018 - 2030
  • Fig. 55 U.S. key country dynamics
  • Fig. 56 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 57 Canada key country dynamics
  • Fig. 58 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 59 Europe
  • Fig. 60 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 61 UK key country dynamics
  • Fig. 62 UK market estimates and forecasts, 2018 - 2030
  • Fig. 63 Germany key country dynamics
  • Fig. 64 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 65 France key country dynamics
  • Fig. 66 France market estimates and forecasts, 2018 - 2030
  • Fig. 67 Italy key country dynamics
  • Fig. 68 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 69 Spain key country dynamics
  • Fig. 70 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 71 Denmark key country dynamics
  • Fig. 72 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 73 Sweden key country dynamics
  • Fig. 74 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 75 Norway key country dynamics
  • Fig. 76 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 77 Asia Pacific
  • Fig. 78 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 79 China key country dynamics
  • Fig. 80 China market estimates and forecasts, 2018 - 2030
  • Fig. 81 Japan key country dynamics
  • Fig. 82 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 83 India key country dynamics
  • Fig. 84 India market estimates and forecasts, 2018 - 2030
  • Fig. 85 Thailand key country dynamics
  • Fig. 86 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 87 South Korea key country dynamics
  • Fig. 88 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 89 Australia key country dynamics
  • Fig. 90 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 91 Latin America
  • Fig. 92 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 93 Brazil key country dynamics
  • Fig. 94 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 95 Mexico key country dynamics
  • Fig. 96 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 97 Argentina key country dynamics
  • Fig. 98 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 99 Middle East and Africa
  • Fig. 100 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 101 South Africa key country dynamics
  • Fig. 102 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 103 Saudi Arabia key country dynamics
  • Fig. 104 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 105 UAE key country dynamics
  • Fig. 106 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 107 Kuwait key country dynamics
  • Fig. 108 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 109 Market share of key market players- Anticoagulants market